Tobacco harm reduction

PMI and BAT Announce Global Patent Settlement

Retrieved on: 
Friday, February 2, 2024
Tobacco, Retail, Smoke, COVID-19, Philip Morris International, Security (finance), Public, Life, Research, British American Tobacco, Intellectual property, BAT, Annual report, Marketing, PMI, IQOS, Food, Privacy, Information, Swedish Match, American Tobacco Company, Sale, Patent, Smoking, Toxicology, ZYN, Form, Tobacco harm reduction, Woman

Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c.

Key Points: 
  • Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c.
  • (BAT) that resolves all ongoing patent infringement litigation between the parties related to our heated tobacco and vapor products.
  • Patent protection is a critical component of the innovation driving PMI’s strategies and the company welcomes this settlement as the best path forward for its business plans.
  • The settlement includes non-monetary provisions between PMI and BAT that resolve all ongoing global patent infringement litigation, encompassing all related injunctions and exclusion orders, and prevents future claims against current heated tobacco and vapor products.

New Clinical Data on Vuse Illustrates Beneficial Public Health Impact of Tobacco Harm Reduction

Retrieved on: 
Tuesday, May 30, 2023
Retail, Health, Biometrics, Tobacco, Clinical Trials, General Health, BAT, Smoker, Emergency medicine, Vuse, Multimedia, Research, Biomarker, Carbon, Bank of England, Risk, WHO, Carboxyhemoglobin, Smoking, Internal, Herbal cigarette, Tobacco harm reduction, Science

View the full release here: https://www.businesswire.com/news/home/20230530005321/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230530005321/en/
    One of the largest ever vapour product studies compared clinical measurements from exclusive Vuse consumers with smokers (Graphic: Business Wire)
    The study compared clinical measurements from exclusive Vuse consumers with smokers.
  • Vuse users have shown significantly lower biomarkers of exposure for priority cigarette smoke toxicants as defined by the World Health Organization (WHO)iii.
  • The data also showed favourable differences between Vuse consumers and smokers across all biomarkers of potential harm measured, with three being statistically significant.
  • The research shows a clear difference between those using Vuse compared to smokers and reinforces the reduced risk potential and role of vapour in Tobacco Harm Reduction.

Reduced-risk* Potential of Velo as Cigarette Alternative Reinforced by Innovative Real-world Study

Retrieved on: 
Tuesday, December 13, 2022
Tobacco, Retail, General Health, Health, BAT, Ageing, Area studies, Person, Drug and Chemical Toxicology, Report, Sumathi Best Television Current Reporting Award, Lyft, Scientific method, Devon Bat Group, Biomarker, Tobacco, ESG, Cancer, Annual report, Cardiovascular disease, Knowledge, American Tobacco Company, OMICS Publishing Group, FDA, Smoke, Food and Drug Administration, Overalls, Tobacco harm reduction, CVD, Smoking, Multimedia, NRT, WHO, DOI, Blood, Urine, Smoker, Vuse, Carbon, Medical imaging, Dietary supplement, Medicinal plants, Food, Velo, Chemical substance

The study provides important new data and insights into the real-world health impact in Velo consumers compared to smokers, former smokers and never smokers.

Key Points: 
  • The study provides important new data and insights into the real-world health impact in Velo consumers compared to smokers, former smokers and never smokers.
  • We have already generated data that shows Velo has a toxicant profile better than snus and comparable to Nicotine Replacement Therapy (NRT)iii.
  • These results add further evidence that supports the important contribution Velo can make to Tobacco Harm Reduction.
  • The study included participants who had been using Velo exclusively for over six months, as well as current smokers, former smokers and never smokers.

Russia HNB, Oral Tobacco, Snus and Nicotine Pouches Regulatory Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Nicotinic agonists, Electronic cigarettes, Snus, Nicotine pouch, Nicotine, Tobacco harm reduction, Heated tobacco product

The "Regulatory Report: Russia - HNB, Oral Tobacco, Snus and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Russia - HNB, Oral Tobacco, Snus and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.
  • Heated tobacco regulation came into force in Russia on 31st July 2020, when it was made equivalent to that for conventional tobacco products.
  • This report offers a detailed look at the current regulation, as well as any proposed regulation, for heated tobacco, oral tobacco and nicotine pouches in Russia.
  • It will cover all areas of the framework from product and labelling restrictions, to advertising, sanctions and taxation.

Argentina Heated Tobacco and Oral Tobacco Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Nicotinic agonists, Electronic cigarettes, Habits, Snus, Heated tobacco product, Nicotine pouch, Chewing tobacco, Nicotine, Tobacco harm reduction, Tobacco smoking

The "Regulatory Report: Argentina - Heated Tobacco and Oral Tobacco" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Argentina - Heated Tobacco and Oral Tobacco" report has been added to ResearchAndMarkets.com's offering.
  • The regulation of heated tobacco and modern oral products, such as tobacco-free nicotine pouches or snus containing tobacco, will remain unchanged in Argentina for the foreseeable future.
  • For the time being, it does not seem to be a priority for the authorities to establish a clear regulatory framework for heated tobacco products, which means that they will remain under the legal framework of tobacco products.
  • This initiative has already been proposed by countries such as the UK and New Zealand, which seek the same by 2030 and 2025 respectively.

On World No Tobacco Day, Foundation for a Smoke-Free World Urges Smokers to Quit or Switch to Harm-Reduction Products

Retrieved on: 
Friday, May 28, 2021
Psychoactive drugs, Health, Health effects of tobacco, Nicotinic agonists, Smoking cessation, Smoking, Substance-related disorders, Nicotine replacement therapy, Tobacco, Smokeless tobacco, Nicotine, Tobacco harm reduction

The calls by the World Health Organization (WHO) for smokers to quit using fairly ineffective interventions suggest we need new approaches.

Key Points: 
  • The calls by the World Health Organization (WHO) for smokers to quit using fairly ineffective interventions suggest we need new approaches.
  • On this WNTD (May 31), the Foundation urges adult smokers to commit to quit smoking combustibles and chewing toxic smokeless tobacco products or switch to a growing range of less harmful nicotine-based alternatives.
  • However, they never mention a role for tobacco harm-reduction (THR) products as part of tobacco control policy.
  • Denying the value and benefits of THR products is irresponsible and blatantly discounts the research showing they can help smokers quit."

Smokefree-UK, a need to fire up commitment to quit smoking

Retrieved on: 
Thursday, May 27, 2021
Smoking cessation, Health effects of tobacco, Human behavior, Psychoactive drugs, Health, Habits, Substance-related disorders, General practice, Smoking, Nicotine replacement therapy, Positions of medical organizations on electronic cigarettes, Tobacco harm reduction

In a paper published this week based on the study, the authors warn about worrying changes in smoking and smoking cessation behaviours.

Key Points: 
  • In a paper published this week based on the study, the authors warn about worrying changes in smoking and smoking cessation behaviours.
  • The COVID-19 situation changed the plans to quit smoking in 36% of smokers and dual users, with only 6% deciding to quit.
  • We need to keep smoking cessation and relapse prevention top on the healthcare agenda and support all smokers to 'commit to quit'.
  • CHRE's philosophy and approach are to bridge the policy and practice gap in delivering smoking cessation treatments and services globally.

Smokefree-UK, a need to fire up commitment to quit smoking

Retrieved on: 
Thursday, May 27, 2021
Smoking cessation, Health effects of tobacco, Human behavior, Psychoactive drugs, Health, Habits, Substance-related disorders, General practice, Smoking, Nicotine replacement therapy, Positions of medical organizations on electronic cigarettes, Tobacco harm reduction

In a paper published this week based on the study, the authors warn about worrying changes in smoking and smoking cessation behaviours.

Key Points: 
  • In a paper published this week based on the study, the authors warn about worrying changes in smoking and smoking cessation behaviours.
  • The COVID-19 situation changed the plans to quit smoking in 36% of smokers and dual users, with only 6% deciding to quit.
  • We need to keep smoking cessation and relapse prevention top on the healthcare agenda and support all smokers to 'commit to quit'.
  • CHRE's philosophy and approach are to bridge the policy and practice gap in delivering smoking cessation treatments and services globally.

State & Local Governments Must Plan to End Tobacco Sales

Retrieved on: 
Monday, May 24, 2021
Tobacco, Smoking in the United States, Psychoactive drugs, Health in the United States, Tobacco control, Cigarettes, Tobacco industry, Cigarette, Action on Smoking and Health, Tobacco harm reduction

So, it's up to state and local governments to follow the lead of Beverly Hills and Manhattan Beach, CA and begin phasing out the sale of tobacco products.

Key Points: 
  • So, it's up to state and local governments to follow the lead of Beverly Hills and Manhattan Beach, CA and begin phasing out the sale of tobacco products.
  • "For decades, tobacco companies have falsely claimed they'd stop selling cigarettes if proven deadly," said ASH Executive Director Laurent Huber.
  • It's up to governments to protect their citizens from tobacco products and from the tobacco industry by planning to phase out the sale of combustible tobacco."
  • The tobacco pandemic death toll rivals that of the COVID-19 pandemic, with one substantial difference: the tobacco pandemic reaches that death toll every year, not just once in a lifetime.

Philip Morris International Inc. (PMI) to Host Webcast of Presentation at 2021 Goldman Sachs Global Staples Forum

Retrieved on: 
Tuesday, May 11, 2021
Tobacco, Retail, Tobacco, Psychoactive drugs, Electronic cigarettes, Cigarettes, Heated tobacco product, Cigarette, Nicotine, Smoke, Electronic cigarette, Tobacco harm reduction

PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S.

Key Points: 
  • PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S.
  • PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke.
  • Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements.
  • PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products.